6492 Stock Overview
Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Senhwa Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$41.10 |
| 52 Week High | NT$62.30 |
| 52 Week Low | NT$40.35 |
| Beta | 0.86 |
| 1 Month Change | -7.64% |
| 3 Month Change | -13.20% |
| 1 Year Change | -15.69% |
| 3 Year Change | -73.57% |
| 5 Year Change | -39.02% |
| Change since IPO | -60.48% |
Recent News & Updates
Shareholder Returns
| 6492 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -1.6% | -0.7% | -1.6% |
| 1Y | -15.7% | -23.7% | 25.9% |
Return vs Industry: 6492 exceeded the TW Biotechs industry which returned -23.7% over the past year.
Return vs Market: 6492 underperformed the TW Market which returned 25.9% over the past year.
Price Volatility
| 6492 volatility | |
|---|---|
| 6492 Average Weekly Movement | 3.4% |
| Biotechs Industry Average Movement | 4.8% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.6% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6492 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6492's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Jin-Ding Huang | www.senhwabio.com |
Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidnarulex and talazoparib in patients with metastatic castration resistant prostate cancer. It is also developing CX-4945-CCA that is in phase I/II clinical trial in combination with gemcitabine for the treatment of patients with cholangiocarcinoma; CX-4945-BCC, which is in phase I, multi-center, open-label, treatment duration increment, expansion, safety, and pharmacodynamic study of CX-4945 administered orally twice daily to patients with advanced basal cell carcinoma; and CX-4945-MB, a pediatric brain tumor consortium that is in phase I/II and surgical study of CX-4945 in patients with recurrent SHH medulloblastoma.
Senhwa Biosciences, Inc. Fundamentals Summary
| 6492 fundamental statistics | |
|---|---|
| Market cap | NT$3.67b |
| Earnings (TTM) | -NT$296.31m |
| Revenue (TTM) | NT$1.00m |
3,666x
P/S Ratio-12.4x
P/E RatioIs 6492 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6492 income statement (TTM) | |
|---|---|
| Revenue | NT$1.00m |
| Cost of Revenue | NT$448.00k |
| Gross Profit | NT$552.00k |
| Other Expenses | NT$296.86m |
| Earnings | -NT$296.31m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.32 |
| Gross Margin | 55.20% |
| Net Profit Margin | -29,630.60% |
| Debt/Equity Ratio | 0% |
How did 6492 perform over the long term?
See historical performance and comparison